Bubendorf/Basel, 7 February 2017 – The Bachem Group (SIX: BANB) announced today the renewal of its supply agreement with AstraZeneca for the peptide active substance Goserelin. The extended partnership enhances the successful cooperation between both companies. Under the terms of the agreement, AstraZeneca will continue acquiring the peptide active substance Goserelin from Bachem for the next five years. Bachem has been supplying AstraZeneca with Goserelin for more than 25 years.
Careers
At Bachem, we believe that our employees make the difference. Representing our corporate culture of passion and commitment, they are the foundation of our success. We therefore strive to attract, retain, and develop highly motivated, well-qualified individuals.
View all jobs
Click here >>
Contact us